Although its exact mechanism in the treatment of partial-onset seizures is unknown, cenobamate has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. The Food ...

SK Life Science has announced the availability of Xcopri (cenobamate) tablets for the treatment of partial-onset seizures in adults.  SK Life Science has announced the availability of Xcopri ...

The Food and Drug Administration on Wednesday approved Eisai’s epilepsy drug Fyompa as a primary treatment for partial-onset seizures in epileptic patients 12 years or older. Here are three things to ...

Forbes contributors publish independent expert analyses and insights. I focus on new drugs and innovations in medical devices. Last week, the FDA approved XCOPRI (cenobamate tablets) to treat ...

child yellow pill medicine Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing. The Food and Drug Administration has expanded ...

October 22, 2009 (Baltimore, Maryland) — A new analysis of 3 clinical trials suggests adjunctive lacosamide may be beneficial for partial-onset seizures. The results were presented here at the 134th ...

This new approval provides clinicians with the option to prescribe VIMPAT to their pediatric patients either as an oral solution or a convenient tablet. 1 This allows for flexible administration ...

If your child has a seizure, it's natural to have plenty of concerns about what exactly happened, why, and what comes next. There are treatments that can help, but a lot depends on the cause of the ...

The FDA has approved an expanded indication for Briviact CV tablets, oral solution and injection, for treating partial-onset seizures among children as young as 1 month. “When a child or infant ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the antiepileptic lacosamide UCB (UCB Pharma SA) for partial-onset ...

This review contrasts the standard of care for focal epilepsy with the complex reality of managing non-lesional and ...

Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion for Eisai's antiepileptic drug (AED) ...